<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JOP</journal-id>
<journal-id journal-id-type="hwp">spjop</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
<journal-title>Journal of Psychopharmacology</journal-title>
<issn pub-type="ppub">0269-8811</issn>
<issn pub-type="epub">1461-7285</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269881112447989</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269881112447989</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Antidepressant-like effect of creatine in mice involves dopaminergic activation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Cunha</surname><given-names>Mauricio P</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Machado</surname><given-names>Daniele G</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Capra</surname><given-names>Juliano C</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Jacinto</surname><given-names>Jardel</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Bettio</surname><given-names>Luis EB</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Rodrigues</surname><given-names>Ana Lúcia S</given-names></name>
</contrib>
<aff id="aff1-0269881112447989">Departamento de Bioquímica, Universidade Federal de Santa Catarina, Florianópolis, Brazil</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0269881112447989">Ana Lúcia Severo Rodrigues, Laboratório de Neurobiologia da Depressão, Departamento de Bioquímica, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina (UFSC), 88040-900, Florianópolis, SC, Brazil Email: <email>analucia@mbox1.com.br</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>11</month>
<year>2012</year>
</pub-date>
<volume>26</volume>
<issue>11</issue>
<fpage>1489</fpage>
<lpage>1501</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>Creatine has been shown to play a significant role in health and disease. However, studies concerning its effect on mood are scarce. This study investigated the effect of creatine (p.o.) in the tail suspension test, a predictive test of antidepressant activity. Creatine reduced the immobility time in the tail suspension test (0.1–1000 mg/kg, male and female mice), without affecting locomotor activity. Furthermore, the involvement of the dopaminergic system in creatine-induced antidepressant-like effect in male mice in the tail suspension test was investigated. The anti-immobility effect of creatine (1 mg/kg) was prevented by the pre-treatment of mice with haloperidol (0.2 mg/kg, intraperitoneal (i.p.) route, non-selective dopamine receptor antagonist), (<italic>R</italic>)-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH23390; 0.05 mg/kg, subcutaneous (s.c.) route, dopamine D<sub>1</sub> receptor antagonist) and sulpiride (50 mg/kg, i.p., dopamine D<sub>2</sub> receptor antagonist). Creatine (0.01 mg/kg, sub-effective dose) in combination with sub-effective doses of (1-phenyl-7,8-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepine) hydrochloride (SKF38393; 0.1 mg/kg, s.c., dopamine D<sub>1</sub> receptor agonist), apomorphine (0.5 µg/kg, i.p., preferential dopamine D<sub>2</sub> receptor agonist) or bupropion (1 mg/kg, p.o., dopamine reuptake inhibitor with subtle activity on noradrenergic reuptake) reduced the immobility time in the tail suspension test as compared with either drug alone. These results indicate that the antidepressant-like effect of creatine is likely mediated by an activation of dopamine D<sub>1</sub> and D<sub>2</sub> receptors.</p>
</abstract>
<kwd-group>
<kwd>Antidepressant</kwd>
<kwd>creatine</kwd>
<kwd>dopaminergic system</kwd>
<kwd>tail suspension test</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0269881112447989" sec-type="intro">
<title>Introduction</title>
<p>Depression is a common mood disorder associated with high rates of morbidity and mortality and with a lifetime prevalence of around 17% (<xref ref-type="bibr" rid="bibr63-0269881112447989">Wong and Licinio, 2001</xref>). Current antidepressant treatments have several drawbacks, since they are ineffective for about 30% of depressed patients, produce frequent and persistent side effects and clinical effects only 3–6 weeks after the beginning of the treatment (<xref ref-type="bibr" rid="bibr45-0269881112447989">Nemeroff and Owens, 2002</xref>). For these reasons, the discovery of new drugs or innovative compounds that could further improve current antidepressant therapies is welcome (<xref ref-type="bibr" rid="bibr8-0269881112447989">Berton and Nestler, 2006</xref>).</p>
<p>Many studies in the neurobiology of depression indicate an important role for dopaminergic system in the pathophysiology and treatment of depression (<xref ref-type="bibr" rid="bibr21-0269881112447989">D’Aquila et al., 2000</xref>; <xref ref-type="bibr" rid="bibr46-0269881112447989">Nestler and Carlezon, 2006</xref>; <xref ref-type="bibr" rid="bibr32-0269881112447989">Kulkarni et al., 2008</xref>). Depressive symptoms may be correlated to reduced dopamine levels and its metabolite homovanillic acid in the brain (<xref ref-type="bibr" rid="bibr42-0269881112447989">Mitani et al., 2006</xref>; <xref ref-type="bibr" rid="bibr54-0269881112447989">Sher et al., 2006</xref>). There are high rates of comorbidity of depression and neurological diseases in which a dopamine dysfunction has an essential role, such as schizophrenia (<xref ref-type="bibr" rid="bibr56-0269881112447989">Siris, 2000</xref>) and Parkinson’s disease (<xref ref-type="bibr" rid="bibr6-0269881112447989">Becker et al., 2010</xref>). Furthermore, bupropion and nomifensine (dopamine reuptake inhibitors) are used for treating depression (<xref ref-type="bibr" rid="bibr27-0269881112447989">Holtzheimer and Nemeroff, 2006</xref>; <xref ref-type="bibr" rid="bibr33-0269881112447989">Leuchter et al., 2009</xref>) and produce antidepressant-like effects in animal models (<xref ref-type="bibr" rid="bibr65-0269881112447989">Yamada et al., 2004</xref>; <xref ref-type="bibr" rid="bibr19-0269881112447989">Cunha et al., 2008</xref>). Moreover, dopamine receptor agonists also have proven antidepressant efficacy in clinical trials and in animal models (<xref ref-type="bibr" rid="bibr57-0269881112447989">Siuciak and Fujiwara, 2004</xref>; <xref ref-type="bibr" rid="bibr16-0269881112447989">Clausius et al., 2009</xref>).</p>
<p>Besides the well-known involvement of monoaminergic systems in the pathophysiology of depression, other targets have been shown to be involved in mood modulation. Noteworthy, several studies have demonstrated alterations in high-energy phosphate metabolism in subjects with depression (<xref ref-type="bibr" rid="bibr29-0269881112447989">Kato et al., 1992</xref>; <xref ref-type="bibr" rid="bibr43-0269881112447989">Moore et al., 1997</xref>; <xref ref-type="bibr" rid="bibr64-0269881112447989">Volz et al., 1998</xref>). Indeed, accumulated evidence suggests the possible involvement of hypoactive prefrontal cerebral energy metabolism in the pathophysiology of mood diseases as unipolar and bipolar depression (<xref ref-type="bibr" rid="bibr30-0269881112447989">Ketter et al., 2001</xref>). It is therefore possible that agents that improve cellular bioenergetics may be useful in the treatment of depression.</p>
<p>Creatine (N-aminoiminomethyl-N-methylglycine), a guanidine compound, is synthesized from glycine, arginine and S-adenosylmethionine in the kidneys, liver and pancreas and, to some extent, brain. However, at least 50% of the creatine content in the organism is derived from dietary intake. It is a substrate for cytosolic and mitochondrial creatine kinases, playing a pivotal role in brain energy homeostasis (<xref ref-type="bibr" rid="bibr3-0269881112447989">Andres et al., 2008</xref>).</p>
<p>A significant role for creatine in pathophysiology of depression has been suggested by several clinical studies. A decreased brain phosphocreatine was reported in severely depressed patients (<xref ref-type="bibr" rid="bibr29-0269881112447989">Kato et al., 1992</xref>). Moreover, an inverse correlation between severity of depression and white matter creatine level was shown in depressed or mixed-state bipolar patients (<xref ref-type="bibr" rid="bibr20-0269881112447989">Dager et al., 2004</xref>). Notably, creatine supplementation has been shown to improve mood in a patient who suffered from post-traumatic stress disorder, depression and fibromyalgia (<xref ref-type="bibr" rid="bibr2-0269881112447989">Amital et al., 2006</xref>) and in unipolar patients with treatment-resistant depression (<xref ref-type="bibr" rid="bibr52-0269881112447989">Roitman et al., 2007</xref>). Also, S-adenosyl-L-methionine, a methyl donator in the synthesis of creatine, was also shown to produce antidepressant effects (<xref ref-type="bibr" rid="bibr49-0269881112447989">Papakostas, 2009</xref>). In addition, a recent study showed that creatine supplementation for five weeks produced a depressant-like effect in male rats, but an antidepressant-like effect in female rats in the forced swimming test (FST) <bold>(</bold><xref ref-type="bibr" rid="bibr1-0269881112447989">Allen et al., 2010</xref>).</p>
<p>Noteworthy, creatine supplementation for seven days, in a clinical trial, was able to increase plasma dopamine and decrease cortisol levels associated with an improvement in mood of subjects with sleep deprivation (<xref ref-type="bibr" rid="bibr36-0269881112447989">McMorris et al., 2006</xref>). In addition, creatine treatment for two years improved mood in patients with Parkinson’s disease (<xref ref-type="bibr" rid="bibr7-0269881112447989">Bender et al., 2006</xref>). Furthermore, in vivo and in vitro studies reported a protective role for creatine against the cell death induced by the dopaminergic neurotoxins MPTP and MPP<sup>+</sup> (<xref ref-type="bibr" rid="bibr38-0269881112447989">Matthews et al., 1999</xref>; <xref ref-type="bibr" rid="bibr4-0269881112447989">Andres et al., 2005</xref>).</p>
<p>The purpose of the present study was, ﬁrst, to examine the effects of creatine administered acutely by oral (p.o.) gavage to female and male mice in the tail suspension test (TST), a predictive test of antidepressant efficacy. Considering that the hypofunction of the dopaminergic system is associated with depression (<xref ref-type="bibr" rid="bibr42-0269881112447989">Mitani et al., 2006</xref>) and the possible modulatory role of creatine on this system (<xref ref-type="bibr" rid="bibr38-0269881112447989">Matthews et al., 1999</xref>; <xref ref-type="bibr" rid="bibr4-0269881112447989">Andres et al., 2005</xref>; <xref ref-type="bibr" rid="bibr36-0269881112447989">McMorris et al., 2006</xref>), the second aim of this study was to investigate a possible influence of the dopaminergic system in the antidepressant-like effect of creatine, in order to give insight into the mechanisms underlying its antidepressant-like effect.</p>
</sec>
<sec id="section2-0269881112447989" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-0269881112447989">
<title>Animals</title>
<p>Male and female Swiss mice (30–40 g) were used in the dose–response curve of creatine in the TST. Male Swiss mice (30–40 g) were used in the experiments that investigated the involvement of the dopaminergic system in the antidepressant-like effect of creatine in the TST. Animals were obtained from the Central Biotery of Universidade Federal de Santa Catarina (UFSC) and kept in the sectorial Biotery of the Department of Biochemistry. They were housed in groups of 14 animals per plastic cage (42 cm × 24 cm × 17 cm) under controlled conditions of light (from 07:00 to 19:00 h) and temperature (21±1°C). Mice were allowed free access to standard laboratory food and tap water, and to adapt to the laboratory environment for at least one week before the behavioral studies. Each experimental group consisted of 7–11 animals. Animals were randomly distributed into speciﬁed experimental groups. All manipulations were carried out between 14:00 and 17:00 h, with each animal used only once. All procedures in this study were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and approved by the Ethics Committee of the Institution. All efforts were made to minimize animals’ suffering and to reduce the number of animals used in the experiments.</p>
</sec>
<sec id="section4-0269881112447989">
<title>Drugs and treatment</title>
<p>The following drugs were used: apomorphine, bupropion hydrochloride, creatine monohydrate, haloperidol, (<italic>R</italic>)-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH23390), (1-phenyl-7,8-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepine) hydrochloride (SKF38393) and sulpiride (all from Sigma Chemical Company, St Louis, MO, USA).</p>
<p>The drugs were administered by intraperitoneal (i.p.) route, except SCH23390 and SKF38393, which were administered by subcutaneous (s.c.) route and creatine and bupropion, which were administered by p.o. route by gavage. All drugs were administered in a constant volume of 10 ml/kg body weight. Drugs were dissolved in saline, except creatine and bupropion, which were diluted in distilled water, haloperidol, which was diluted in saline with 5% ethanol, and sulpiride, which was diluted in saline with 5% dimethylsulfoxide (DMSO). Control animals received the appropriate vehicle.</p>
</sec>
<sec id="section5-0269881112447989">
<title>Experimental design</title>
<p>In order to investigate the antidepressant-like effect produced by an oral administration of creatine monohydrate, it was administered to female or male mice at the dose range 0.01–1000 mg/kg, 60 min before the TST or open-field test. Bupropion (10 mg/kg, p.o., a dopamine reuptake inhibitor with subtle activity on noradrenergic reuptake) was used as a positive control. It was administered 60 min before the TST or open-field paradigm. The active dose of bupropion was chosen based on a previous study (<xref ref-type="bibr" rid="bibr19-0269881112447989">Cunha et al., 2008</xref>).</p>
<p>In order to assure that a dopamine D<sub>1</sub> and D<sub>2</sub> receptor activation is associated with an antidepressant response (control experiments), male mice were given SKF38393 (s.c.), a synthetic compound of the benzodiazepine chemical class which acts as a selective dopamine D<sub>1</sub> receptor agonist (<xref ref-type="bibr" rid="bibr59-0269881112447989">Stoof and Kebabian, 1984</xref>; <xref ref-type="bibr" rid="bibr41-0269881112447989">Missale et al., 1998</xref>), or apomorphine (intraperitoneally), a non-selective dopamine receptor agonist which preferentially activates dopamine D<sub>2</sub> receptors (<xref ref-type="bibr" rid="bibr41-0269881112447989">Missale et al., 1998</xref>), with 16.0% more preference for D<sub>2</sub> receptor than for D<sub>1</sub> receptor subtype (<xref ref-type="bibr" rid="bibr40-0269881112447989">Millan et al., 2002</xref>) at doses: 0.1–3 mg/kg and 0.5–50 µg/kg, respectively, 30 min before the TST or open-field test. The dose range of SKF38393 and apomorphine was selected on the basis of previous literature data (<xref ref-type="bibr" rid="bibr47-0269881112447989">Nikulina et al., 1991</xref>; <xref ref-type="bibr" rid="bibr62-0269881112447989">Vamvakidès, 1999</xref>; <xref ref-type="bibr" rid="bibr50-0269881112447989">Renard et al., 2001</xref>).</p>
<p>In the experiments designed to verify the involvement of the dopaminergic system in the mechanisms underlying the antidepressant-like effect of creatine in the TST, male mice were pre-treated with vehicle (control group), haloperidol (0.2 mg/kg, intraperitoneal (i.p.) route, a non-selective dopamine receptor antagonist), SCH23390 (0.05 mg/kg, s.c., a dopamine D<sub>1</sub> receptor antagonist) or sulpiride (50 mg/kg, i.p., a dopamine D<sub>2</sub> receptor antagonist), and 30 min later they received vehicle or creatine (1 mg/kg, p.o.). After 60 min, the TST or open-field test was carried out (<xref ref-type="bibr" rid="bibr34-0269881112447989">Machado et al., 2009</xref>; <xref ref-type="bibr" rid="bibr9-0269881112447989">Binfaré et al., 2010</xref>). The selectivity of the dopamine receptor antagonists used in the present study was reported in previous studies (<xref ref-type="bibr" rid="bibr15-0269881112447989">Christensen et al.,1984</xref>; <xref ref-type="bibr" rid="bibr26-0269881112447989">Hyttel, 1984</xref>; <xref ref-type="bibr" rid="bibr66-0269881112447989">Zarrindast and Moghaddampour, 1989</xref>; <xref ref-type="bibr" rid="bibr41-0269881112447989">Missale et al., 1998</xref>).</p>
<p>Furthermore, in another experimental protocol, mice were pre-treated with vehicle (control group) or SCH23390 (0.05 mg/kg, s.c.) and 30 min later they received vehicle or SKF38393 (3 mg/kg, s.c.), 30 min before being tested in the TST or open-field test. In addition, in another set of experiments, mice were pre-treated with sulpiride (50 mg/kg, i.p.) and 30 min later they received vehicle or apomorphine (50 µg/kg, i.p.), 30 min before being tested in the TST or open-field paradigm.</p>
<p>We also investigated the synergistic effect of a sub-effective dose of creatine (0.01 mg/kg, p.o.) with sub-effective doses of SKF38393 (0.1 mg/kg, s.c., a selective dopamine D<sub>1</sub> receptor agonist) or apomorphine (0.5 µg/kg, i.p., a non-selective dopamine receptor agonist which activates both dopamine D<sub>1</sub> and D<sub>2</sub> receptors, although with preference for dopamine D<sub>2</sub> receptor subtype). Creatine or vehicle was administered 30 min before these agonists. A further 30 min was allowed to elapse before the animals were tested in the TST.</p>
<p>In order to investigate the potential synergistic effect of a sub-effective dose of creatine (0.01 mg/kg, p.o.) with a sub-effective dose of bupropion (1 mg/kg, p.o.) in the TST, creatine or vehicle administration was followed by another immediate administration of bupropion or vehicle 60 min before the TST or open-ﬁeld test. The sub-effective dose of bupropion was chosen based on previous studies (<xref ref-type="bibr" rid="bibr19-0269881112447989">Cunha et al., 2008</xref>; <xref ref-type="bibr" rid="bibr9-0269881112447989">Binfaré et al., 2010</xref>).</p>
<p>The doses and routes of administration of the dopaminergic agents used in the present study (dopamine receptor antagonists and agonists and bupropion) were chosen based on previous studies and were reported to cause no effect in the ambulatory behavior of mice (<xref ref-type="bibr" rid="bibr62-0269881112447989">Vamvakidès, 1999</xref>; <xref ref-type="bibr" rid="bibr50-0269881112447989">Renard et al., 2001</xref>; <xref ref-type="bibr" rid="bibr65-0269881112447989">Yamada et al., 2004</xref>; <xref ref-type="bibr" rid="bibr19-0269881112447989">Cunha et al., 2008</xref>; <xref ref-type="bibr" rid="bibr9-0269881112447989">Binfaré et al., 2010</xref>; <xref ref-type="bibr" rid="bibr13-0269881112447989">Capra et al., 2010</xref>).</p>
</sec>
<sec id="section6-0269881112447989">
<title>Behavioral tests</title>
<sec id="section7-0269881112447989">
<title>TST</title>
<p>The TST has become one of the most widely used models for assessing antidepressant-like activity in mice. The test is based on the fact that animals subjected to the short-term inescapable stress of being suspended by their tail will develop an immobile posture. The total duration of immobility induced by tail suspension was measured according to the method described by <xref ref-type="bibr" rid="bibr58-0269881112447989">Steru et al. (1985)</xref>. Brieﬂy, mice both acoustically and visually isolated were suspended 50 cm above the ﬂoor by adhesive tape placed approximately 1 cm from the tip of the tail. Immobility time was recorded during a 6 min period. Mice were considered immobile only when they hung passively and completely motionless. The immobility time was recorded by an observer blind to the drug treatment (<xref ref-type="bibr" rid="bibr19-0269881112447989">Cunha et al., 2008</xref>; <xref ref-type="bibr" rid="bibr34-0269881112447989">Machado et al., 2009</xref>; <xref ref-type="bibr" rid="bibr9-0269881112447989">Binfaré et al., 2010</xref>).</p>
</sec>
<sec id="section8-0269881112447989">
<title>Open-field test</title>
<p>To assess the possible effects of creatine on locomotor activity, mice were evaluated in the open-field paradigm as previously described (<xref ref-type="bibr" rid="bibr35-0269881112447989">Machado et al., 2007</xref>, <xref ref-type="bibr" rid="bibr34-0269881112447989">2009</xref>). Mice were individually placed in a wooden box (40 cm × 60 cm × 50 cm) with the floor divided into 12 equal rectangles. The number of rectangles crossed by the animal with its four paws (crossing) and rising of the front paws (rearing) was counted during a period of 6 min. The number of crossings was considered as indicative of locomotor activity and number of rearings was an indication of exploratory behavior. The behavior was recorded by an observer blind to the drug treatment. The ﬂoor of the open-ﬁeld apparatus was cleaned with 10% ethanol between tests.</p>
</sec></sec>
<sec id="section9-0269881112447989">
<title>Statistical analysis</title>
<p>Comparisons between experimental and control groups were performed by one-way (dose-response curve of creatine in the TST and open-field test in male and female mice) or two-way (experiments dealing with the involvement of the dopaminergic system in the effect of creatine in the TST in male mice) analysis of variance (ANOVA) followed by Tukey’s HSD test when the <italic>F</italic> value was significant, as indicated on figure captions. A value of <italic>p</italic> &lt; 0.05 was considered to be significant.</p>
</sec></sec>
<sec id="section10-0269881112447989" sec-type="results">
<title>Results</title>
<sec id="section11-0269881112447989">
<title>Effect of acute treatment with creatine on the immobility time in the TST and on the number of crossings in the open-field test in male and female mice</title>
<p>Creatine administration at doses of 0.01–1000 mg/kg was tested in the TST in male and female mice. Creatine significantly reduced the immobility time in TST at doses of 0.1, 1, 10, 100 and 1000 mg/kg in female (20.7%, 21.7%, 35.0%, 24.5%, 28.3% of reduction, respectively, <xref ref-type="fig" rid="fig1-0269881112447989">Figure 1(a)</xref>) and male (27.4%, 39.2%, 33.7%, 32.3% and 32.2% of reduction, respectively, <xref ref-type="fig" rid="fig1-0269881112447989">Figure 1(e)</xref>) mice as compared with the control group. The one-way ANOVA revealed a significant effect of treatment in female (<italic>F</italic>(6,56)=7.10; <italic>p</italic> &lt; 0.01) and male (<italic>F</italic>(6,47) = 6.30; <italic>p</italic> &lt; 0.01) mice. Bupropion (10 mg/kg, a positive control) significantly reduced the immobility time in TST in female (44.9% of reduction, <xref ref-type="fig" rid="fig1-0269881112447989">Figure 1(b)</xref>) and male (18.0% of reduction, <xref ref-type="fig" rid="fig1-0269881112447989">Figure 1(f)</xref>) mice as compared with the control group. The one-way ANOVA revealed a significant effect of bupropion treatment in female (<italic>F</italic>(1,16)=48.72; <italic>p</italic> &lt; 0.01) and male (<italic>F</italic>(1,15) = 8.43; <italic>p</italic> &lt; 0.05) mice.</p>
<fig id="fig1-0269881112447989" position="float">
<label>Figure 1.</label>
<caption>
<p>Effect of treatment with creatine (0.01–1000 mg/kg, p.o.) or bupropion (10 mg/kg, p.o., dopamine reuptake inhibitor) on the immobility time in the tail suspension test (TST) and number of crossings in the open-field test (OFT) in female (panels (a), (b), (c) and (d), respectively) and male (panels (e), (f), (g) and (h), respectively) mice. Each column represents the mean + SEM.</p>
<p>*<italic>p</italic> &lt;0.05; **<italic>p</italic> &lt;0.01 compared with the vehicle-treated control (c) (one-way ANOVA followed by Tukey’s HSD post-hoc test).</p>
</caption>
<graphic xlink:href="10.1177_0269881112447989-fig1.tif"/>
</fig>
<p>Furthermore, creatine administration at doses of 0.01–1000 mg/kg and bupropion (10 mg/kg) were tested in the open-field test in male and female mice. The administration of creatine did not alter the number of crossings in the open-field test in female (<xref ref-type="fig" rid="fig1-0269881112447989">Figure 1(c)</xref>) and male (<xref ref-type="fig" rid="fig1-0269881112447989">Figure 1(g)</xref>) mice). Moreover, bupropion did not significantly alter the number of crossings in the open-field test in female <xref ref-type="fig" rid="fig1-0269881112447989">Figure 1(d)</xref> and male (<xref ref-type="fig" rid="fig1-0269881112447989">Figure 1(h)</xref>) mice as compared with the control group.</p>
</sec>
<sec id="section12-0269881112447989">
<title>Effect of acute treatment with dopamine receptor agonists on the immobility time in the TST and on the number of crossings in the open-field test</title>
<p>The SKF38393 (dopamine D<sub>1</sub> receptor agonist) administration at a dose of 3 mg/kg reduced the immobility time in mice (45.0% of reduction, <xref ref-type="fig" rid="fig2-0269881112447989">Figure 2(a)</xref>). The one-way ANOVA revealed a significant effect of SKF38393 treatment (<italic>F</italic>(3,26) = 12.26; <italic>p</italic> &lt; 0.01).</p>
<fig id="fig2-0269881112447989" position="float">
<label>Figure 2.</label>
<caption>
<p>Effect of the treatment with SKF38393 (0.1–3 mg/kg, s.c., a dopamine D<sub>1</sub> receptor agonist) and apomorphine (0.5–50 µg/kg, i.p., a preferential dopamine D<sub>2</sub> receptor agonist) on the immobility time in the tail suspension test (TST) (panels (a) and (b), respectively) and on the number of crossings in the open-field test (OFT) (panels (c) and (d), respectively) in male mice. Each column represents the mean + SEM.</p>
<p>*<italic>p</italic> &lt;0.05; **<italic>p</italic> &lt;0.01 compared with the vehicle-treated control (c) (one-way ANOVA followed by Tukey’s HSD post-hoc test).</p>
</caption>
<graphic xlink:href="10.1177_0269881112447989-fig2.tif"/>
</fig>
<p>Furthermore, SKF38393 administration at doses of 0.1–3 mg/kg was tested in the open-field test (<xref ref-type="fig" rid="fig2-0269881112447989">Figure 2(c)</xref>). The administration of SKF38393 did not significantly alter the number of crossings in the open-field test.</p>
<p>The apomorphine administration at dose of 50 µg/kg reduced (28.9%) the immobility time (<xref ref-type="fig" rid="fig2-0269881112447989">Figure 2(b)</xref>) in the TST. The one-way ANOVA revealed a significant effect of apomorphine treatment (<italic>F</italic>(3,32) = 4.39; <italic>p</italic> &lt; 0.05).</p>
<p>Moreover, apomorphine administration at doses of 0.5– 50 µg/kg was tested in the open-field test (<xref ref-type="fig" rid="fig2-0269881112447989">Figure 2(d)</xref>). The administration of apomorphine did not alter the number of crossings in this test.</p>
</sec>
<sec id="section13-0269881112447989">
<title>Influence of the pre-treatment with dopamine receptor antagonists on the effect of creatine in the TST and open-field test</title>
<p>The result depicted in <xref ref-type="fig" rid="fig3-0269881112447989">Figure 3(a)</xref> shows that the anti-immobility effect of creatine (1 mg/kg) was prevented by pre-treatment of mice with the non-selective dopamine receptor antagonist haloperidol (0.2 mg/kg) in the TST. A two-way ANOVA showed significant differences for haloperidol treatment (<italic>F</italic>(1,28) = 13.35; <italic>p</italic> &lt; 0.01), creatine treatment (<italic>F</italic>(1,28) = 11.00; <italic>p</italic> &lt; 0.01) and haloperidol × creatine treatment interaction (<italic>F</italic>(1,28) = 7.74; <italic>p</italic> &lt; 0.01).</p>
<fig id="fig3-0269881112447989" position="float">
<label>Figure 3.</label>
<caption>
<p>Effect of pre-treatment of mice with haloperidol (0.2 mg/kg, i.p., non-selective dopamine receptor antagonist) and treatment with creatine (1 mg/kg, p.o.) on the immobility time in the tail suspension test (TST) (panel (a)) and on the number of crossings in the open-field test (OFT) (panel (b)). Each column represents the mean + SEM.</p>
<p>**<italic>p</italic> &lt;0.01 compared with the vehicle-treated control; <sup>#</sup><italic>p</italic>&lt;0.01 as compared with the same group pre-treated with vehicle (two-way ANOVA followed by Tukey’s HSD post-hoc test).</p>
</caption>
<graphic xlink:href="10.1177_0269881112447989-fig3.tif"/>
</fig>
<p>The number of crossings in the open-field test was not significantly altered by haloperidol (0.2 mg/kg) and creatine (1 mg/kg) administrations (<xref ref-type="fig" rid="fig3-0269881112447989">Figure 3(b)</xref>).</p>
<p>The pre-treatment of mice with the dopamine D<sub>1</sub> receptor antagonist SCH23390 (0.05 mg/kg) prevented the antidepressant-like action of creatine in the TST (<xref ref-type="fig" rid="fig4-0269881112447989">Figure 4(a)</xref>). A two-way ANOVA showed significant differences for SCH23390 treatment (<italic>F</italic>(1,36) = 26.76; <italic>p</italic> &lt; 0.01), creatine treatment (<italic>F</italic>(1,36) = 17.38; <italic>p</italic> &lt; 0.01) and SCH23390 × creatine interaction (<italic>F</italic>(1,36) = 9.05; <italic>p</italic> &lt; 0.01). Also, the pre-treatment of mice with the dopamine D<sub>1</sub> receptor antagonist SCH23390 (0.05 mg/kg) prevented the antidepressant-like action of SKF38393 (3 mg/kg), used as a positive control (<xref ref-type="fig" rid="fig4-0269881112447989">Figure 4(b)</xref>). A two-way ANOVA showed significant differences for SCH23390 treatment (<italic>F</italic>(1,31) = 40.71; <italic>p</italic> &lt; 0.01), SKF38393 treatment (<italic>F</italic>(1,31) = 57.23; <italic>p</italic> &lt; 0.01) and SCH23390 × SKF38393 interaction (<italic>F</italic>(1,31) = 14.26; <italic>p</italic> &lt; 0.01).</p>
<fig id="fig4-0269881112447989" position="float">
<label>Figure 4.</label>
<caption>
<p>Effect of pre-treatment of mice with SCH23390 (0.05 mg/kg, s.c., a dopamine D<sub>1</sub> receptor antagonist) and treatment with creatine (1 mg/kg, p.o.) or SKF38393 (3 mg/kg, s.c., a dopamine D<sub>1</sub> receptor agonist) on the immobility time in the tail suspension test (TST) (panels (a) and (b), respectively) and on the number of crossings in the open-field test (OFT) (panels (c) and (d), respectively). Each column represents the mean + SEM.</p>
<p>*<italic>p</italic> &lt;0.05, **<italic>p</italic> &lt;0.01 compared with the vehicle-treated control; <sup>#</sup><italic>p</italic>&lt;0.01 as compared with the same group pre-treated with vehicle (two-way ANOVA followed by Tukey’s HSD post-hoc test).</p>
</caption>
<graphic xlink:href="10.1177_0269881112447989-fig4.tif"/>
</fig>
<p><xref ref-type="fig" rid="fig4-0269881112447989">Figure 4(c)</xref> shows that the administration of SCH23390 (0.05 mg/kg) in combination with creatine (1 mg/kg) significantly increased the number of crossings in the open-field test. A two-way ANOVA revealed a main effect for SCH23390 treatment (<italic>F</italic>(1,38) = 4.95; <italic>p</italic> &lt; 0.05) and SCH23390 × creatine interaction (<italic>F</italic>(1,38) = 6.98; <italic>p</italic> &lt; 0.05), but not for creatine treatment (<italic>p</italic> &gt; 0.05). In addition, the number of crossings in the open-field test was not significantly altered by pre-treatment with SCH23390 (0.05 mg/kg) and treatment with SKF38393 (3 mg/kg) (<xref ref-type="fig" rid="fig4-0269881112447989">Figure 4(d)</xref>).</p>
<p>The pre-treatment of mice with the dopamine D<sub>2</sub> receptor antagonist sulpiride (50 mg/kg) prevented the antidepressant-like action of creatine in the TST (<xref ref-type="fig" rid="fig5-0269881112447989">Figure 5(a)</xref>). A two-way ANOVA showed significant differences for sulpiride treatment (<italic>F</italic>(1,28) = 83.08; <italic>p</italic> &lt; 0.01), creatine treatment (<italic>F</italic>(1,28) = 11.01; <italic>p</italic> &lt; 0.01) and sulpiride × creatine interaction (<italic>F</italic>(1,28) = 18.06; <italic>p</italic> &lt; 0.01). Also, the pre-treatment of mice with the dopamine D<sub>2</sub> receptor antagonist sulpiride (50 mg/kg) prevented the antidepressant-like action of apomorphine (50 µg/kg), used as a positive control (<xref ref-type="fig" rid="fig5-0269881112447989">Figure 5(b)</xref>). A two-way ANOVA showed significant differences for sulpiride treatment (<italic>F</italic>(1,29) = 24.83; <italic>p</italic> &lt; 0.01), apomorphine treatment (<italic>F</italic>(1,29) = 29.38; <italic>p</italic> &lt; 0.01) and sulpiride × apomorphine interaction (<italic>F</italic>(1,29) = 7.13; <italic>p</italic> &lt; 0.05).</p>
<fig id="fig5-0269881112447989" position="float">
<label>Figure 5.</label>
<caption>
<p>Effect of pre-treatment of mice with sulpiride (50 mg/kg, i.p., a dopamine D<sub>2</sub> receptor antagonist) on the anti-immobility effect creatine (1 mg/kg, p.o.) or apomorphine (50 µg/kg, i.p., a preferential dopamine D<sub>2</sub> receptor agonist) in the tail suspension test (TST) (panels (a) and (b), respectively) and on the number of crossings in the open-field test (OFT) (panels (c) and (d), respectively). Each column represents the mean + SEM.</p>
<p>**<italic>p</italic> &lt;0.01 compared with the vehicle-treated control; <sup>#</sup><italic>p</italic>&lt;0.01 as compared with the same group pre-treated with vehicle (two-way ANOVA followed by Tukey’s HSD post-hoc test).</p>
</caption>
<graphic xlink:href="10.1177_0269881112447989-fig5.tif"/>
</fig>
<p>Furthermore, the number of crossings in the open-field test was not significantly altered by sulpiride (50 mg/kg) administered alone or in combination with creatine (1 mg/kg) (<xref ref-type="fig" rid="fig5-0269881112447989">Figure 5(c)</xref>). Moreover, <xref ref-type="fig" rid="fig5-0269881112447989">Figure 5(d)</xref> shows that the administration of sulpiride alone or in combination with apomorphine (50 µg/kg) did not significantly affect the number of crossings in the open-field test.</p>
</sec>
<sec id="section14-0269881112447989">
<title>Effect of the combined administration of creatine with dopamine receptor agonists on the immobility time in the TST and on the number of crossings in the open-field test</title>
<p>The D<sub>1</sub> receptor agonist SKF38393 (0.1 mg/kg), administered at a sub-effective dose, exhibited a potent antidepressant-like effect when combined with a sub-effective dose of creatine (0.01 mg/ kg) in the TST in male mice (32.4% of reduction in the immobility time) (<xref ref-type="fig" rid="fig6-0269881112447989">Figure 6(a)</xref>). A two-way ANOVA showed significant differences for creatine treatment (<italic>F</italic>(1,38) = 17.13; <italic>p</italic> &lt; 0.01), SKF38393 treatment (<italic>F</italic>(1,38) = 9.21; <italic>p</italic> &lt; 0.01) and creatine × SKF 38393 interaction (<italic>F</italic>(1,38) = 4.52; <italic>p</italic> &lt; 0.01).</p>
<fig id="fig6-0269881112447989" position="float">
<label>Figure 6.</label>
<caption>
<p>Effect of the treatment with sub-effective doses of creatine (0.01 mg/kg, p.o.) in combination with SKF38393 (0.1 mg/kg, s.c., a dopamine D<sub>1</sub> receptor agonist) on the immobility time in the tail suspension test (TST) (panel (a)) and on the number of crossings in the open-field test (OFT) (panel (b)). Each column represents the mean + SEM.</p>
<p>**<italic>p</italic> &lt;0.01 compared with the vehicle-treated control (two-way ANOVA followed by Tukey’s HSD post-hoc test).</p>
</caption>
<graphic xlink:href="10.1177_0269881112447989-fig6.tif"/>
</fig>
<p>In addition, <xref ref-type="fig" rid="fig6-0269881112447989">Figure 6(b)</xref> shows that the administration of SKF38393 (0.1 mg/kg) alone or in combination with creatine (0.01 mg/kg) did not significantly affect the number of crossings in the open-field test.</p>
<p>Also, the preferential D<sub>2</sub> receptor agonist apomorphine (0.5 µg/kg), administered at a sub-effective dose, exhibited a potent antidepressant-like effect when combined with a sub-effective dose of creatine (0.01 mg/ kg) in the TST in male mice (32.3% of reduction in the immobility time) (<xref ref-type="fig" rid="fig7-0269881112447989">Figure 7(a)</xref>). A two-way ANOVA showed significant differences for creatine treatment (<italic>F</italic>(1,34) = 28.89; <italic>p</italic> &lt; 0.01), apomorphine treatment (<italic>F</italic>(1,34) = 14.24; <italic>p</italic> &lt; 0.01) and creatine × apomorphine interaction (<italic>F</italic>(1,34) = 9.45; <italic>p</italic> &lt; 0.01).</p>
<fig id="fig7-0269881112447989" position="float">
<label>Figure 7.</label>
<caption>
<p>Effect of the treatment with sub-effective doses of creatine (0.01 mg/kg, p.o.) in combination with apomorphine (0.5 µg/kg, i.p., a preferential dopamine D<sub>2</sub> receptor agonist) on the immobility time in the tail suspension test (TST) (panel (a)) and on the number of crossings in the open-field test (OFT) (panel (b)). Each column represents the mean + SEM.</p>
<p>**<italic>p</italic> &lt;0.01 compared with the vehicle-treated control (two-way ANOVA followed by Tukey’s HSD post-hoc test).</p>
</caption>
<graphic xlink:href="10.1177_0269881112447989-fig7.tif"/>
</fig>
<p>In addition, <xref ref-type="fig" rid="fig7-0269881112447989">Figure 7(b)</xref> shows that the administration of apomorphine (0.5 µg/kg) alone or in combination with creatine (0.01 mg/kg) did not significantly affect the number of crossings in open-field test.</p>
</sec>
<sec id="section15-0269881112447989">
<title>Effect of the combined treatment with creatine and bupropion on the immobility time in the TST and on the number of crossings in the open-field test</title>
<p>Bupropion, administered at a sub-effective dose (1 mg/kg), exhibited a potent antidepressant-like effect when combined with a sub-effective dose of creatine (0.01 mg/kg) in the TST (56.14% of reduction in the immobility time), as compared with the control group or with either drug alone (<xref ref-type="fig" rid="fig8-0269881112447989">Figure 8(a)</xref>). A two-way ANOVA showed significant differences for bupropion treatment (<italic>F</italic>(1,30) = 31.13; <italic>p</italic> &lt; 0.01), creatine treatment (<italic>F</italic>(1,30) = 11.51; <italic>p</italic> &lt; 0.01) and bupropion × creatine interaction (<italic>F</italic>(1,30) = 18.57; <italic>p</italic> &lt; 0.01). Moreover, the number of crossings in the open-field test was not significantly altered by the coadministration of creatine (0.01 mg/kg) with bupropion (1 mg/kg) (<xref ref-type="fig" rid="fig8-0269881112447989">Figure 8(b)</xref>).</p>
<fig id="fig8-0269881112447989" position="float">
<label>Figure 8.</label>
<caption>
<p>Effect of treatment with creatine (0.01 mg/kg, p.o.) in combination with bupropion (1 mg/kg, p.o., a dopamine reuptake inhibitor) at sub-effective doses on the immobility time in the tail suspension test (TST) (panel (a)) and on the number of crossings in the open-field test (OFT) (panel (b)). Each column represents the mean + SEM.</p>
<p>**<italic>p</italic> &lt;0.01 compared with the vehicle-treated control (two-way ANOVA followed by Tukey’s HSD post-hoc test).</p>
</caption>
<graphic xlink:href="10.1177_0269881112447989-fig8.tif"/>
</fig>
<p>Noteworthy, neither creatine nor any pharmacological agent alone or in combination altered the number of rearings in the open-field test (data not shown).</p>
</sec></sec>
<sec id="section16-0269881112447989" sec-type="discussion">
<title>Discussion</title>
<p>Although aerobic glycolysis is the primary pathway of ATP synthesis in brain, a rapid, available, alternative source for ATP synthesis is the creatine kinase/phosphocreatine system, which can operate via substrate level phosphorylation to equilibrate adenine nucleotides with phosphocreatine and creatine. ATP levels are regulated by the brain-specific isoform of creatine kinase along with the mitochondrial isoform and their substrates creatine and phosphocreatine (<xref ref-type="bibr" rid="bibr3-0269881112447989">Andres et al., 2008</xref>). There are several pieces of evidence indicating that brain bioenergetics is a therapeutic target for the treatment of depression (<xref ref-type="bibr" rid="bibr44-0269881112447989">Moretti et al., 2003</xref>; <xref ref-type="bibr" rid="bibr12-0269881112447989">Burroughs and French, 2007</xref>). Novel therapeutic strategies for the treatment of depressive disorders include the evaluation of the mood effects of agents that alter energy parameters. Accordingly, two open-labeled studies found that creatine can significantly improve depressive mood (<xref ref-type="bibr" rid="bibr2-0269881112447989">Amital et al., 2006</xref>; <xref ref-type="bibr" rid="bibr52-0269881112447989">Roitman et al., 2007</xref>). Consistent with this finding, our results clearly show that creatine given systemically by oral gavage is effective in reducing the immobility time in the TST, which indicates an antidepressant-like property of this ergogenic compound, in this predictive test of antidepressant action (<xref ref-type="bibr" rid="bibr58-0269881112447989">Steru et al., 1985</xref>; <xref ref-type="bibr" rid="bibr18-0269881112447989">Cryan et al., 2005</xref>).</p>
<p>It is interesting to note that in our study the acute administration of creatine at a wide dose range (0.1–1000 mg/kg) showed a similar behavioral profile in male and female mice in the TST. Noteworthy, creatine is considered as a widespread, effective and safe ergogenic aid, being used more by men than by women. Taking this information into account, the doses of 0.01 (sub-effective dose) and 1 mg/kg (effective dose) of creatine were chosen to be used in all the further experiments in male mice.</p>
<p>The acute administration of imipramine and ketamine, compounds with antidepressant properties, was reported to increase creatine kinase activity in striatum, cerebral cortex and cerebellum (<xref ref-type="bibr" rid="bibr5-0269881112447989">Assis et al., 2009</xref>). Thus, it is tempting to speculate that the antidepressant-like effect of creatine (substrate for creatine kinase) may be dependent, at least in part, by a modulation of creatine kinase activity. Moreover, a single exposition to FST decreases the creatine-containing compound levels in the dorsolateral prefrontal cortex (<xref ref-type="bibr" rid="bibr31-0269881112447989">Kim et al., 2010</xref>). Thus, in the present study, the antidepressant-like effect of creatine in the TST may be dependent on an acute modulation of creatine content.</p>
<p>It should be considered that drugs that enhance locomotor activity may give a false positive effect, whereas drugs decreasing locomotion may give a false negative result in the TST (<xref ref-type="bibr" rid="bibr10-0269881112447989">Borsini and Meli, 1988</xref>). Thus, in order to rule out the possibility that the reduction in the immobility time elicited by a drug is due to an enhancement in the locomotor activity, tests that assess the locomotor activity of mice, mainly the open-field test, are usually employed. In this study, we demonstrated that creatine does not exert a psychostimulant effect in the open-field test when administered at doses that cause antidepressant-like action.</p>
<p>Since dopamine is the main neurotransmitter involved in the mesolimbic reward pathways, it has been proposed that an increase in dopaminergic neurotransmission might counteract the anhedonia that is a prominent symptom of depression (<xref ref-type="bibr" rid="bibr21-0269881112447989">D’Aquila et al., 2000</xref>). Our recent studies have reported the implication of dopamine as one of the important targets in the action of antidepressant agents (<xref ref-type="bibr" rid="bibr35-0269881112447989">Machado et al., 2007</xref>, <xref ref-type="bibr" rid="bibr34-0269881112447989">2009</xref>; <xref ref-type="bibr" rid="bibr14-0269881112447989">Cardoso et al., 2009</xref>; <xref ref-type="bibr" rid="bibr9-0269881112447989">Binfaré et al., 2010</xref>; <xref ref-type="bibr" rid="bibr23-0269881112447989">Freitas et al., 2010</xref>). In addition, some evidence suggest that patients with depression, as well as schizophrenia, another disease known to be associated with a dopaminergic dysfunction, have a significant reduction in brain creatine levels (<xref ref-type="bibr" rid="bibr29-0269881112447989">Kato et al., 1992</xref>; <xref ref-type="bibr" rid="bibr20-0269881112447989">Dager et al., 2004</xref>; <xref ref-type="bibr" rid="bibr48-0269881112447989">Ongür et al., 2009</xref>). Reinforcing the relationship between creatine and the dopaminergic system, in vivo and in vitro studies reported a protective role for creatine against the cell death induced by the dopaminergic neurotoxins MPTP and MPP<sup>+</sup> (<xref ref-type="bibr" rid="bibr38-0269881112447989">Matthews et al., 1999</xref>; <xref ref-type="bibr" rid="bibr4-0269881112447989">Andres et al., 2005</xref>). Moreover, creatine supplementation for seven days, in a clinical trial, was able to increase the plasma dopamine levels and promoted improvement in mood (<xref ref-type="bibr" rid="bibr36-0269881112447989">McMorris et al., 2006</xref>). Therefore, the present study investigates the possible influence of the dopaminergic system in antidepressant-like effect of creatine in the TST.</p>
<p>The present results suggest that the antidepressant-like effect of creatine in the TST is at least in part dependent on an interaction with the dopamine D<sub>1</sub> receptor, since the pre-treatment of mice with haloperidol or SCH23390 has significantly prevented the antidepressant-like effect evoked by creatine in the TST. Our recent studies have reported that SCH23390 prevented the antidepressant-like effect of antidepressant compounds in the TST (<xref ref-type="bibr" rid="bibr35-0269881112447989">Machado et al., 2007</xref>, <xref ref-type="bibr" rid="bibr34-0269881112447989">2009</xref>; <xref ref-type="bibr" rid="bibr9-0269881112447989">Binfaré et al., 2010</xref>; <xref ref-type="bibr" rid="bibr23-0269881112447989">Freitas et al., 2010</xref>). The antidepressant-like properties of antidepressants from different classes (monoamine oxidase B inhibitors, serotonin reuptake inhibitors, tricyclics and the dopamine reuptake inhibitors) were prevented by SCH23390 in predictive tests of antidepressant action (<xref ref-type="bibr" rid="bibr24-0269881112447989">Gambarana et al., 1995</xref>; <xref ref-type="bibr" rid="bibr50-0269881112447989">Renard et al., 2001</xref>; <xref ref-type="bibr" rid="bibr55-0269881112447989">Shimazu et al., 2005</xref>; <xref ref-type="bibr" rid="bibr9-0269881112447989">Binfaré et al., 2010</xref>; <xref ref-type="bibr" rid="bibr39-0269881112447989">Melo et al., 2011</xref>). In the present study, the reversal of the antidepressant-like effect of creatine elicited by SCH23390 in the TST cannot be attributed to motor impairment, since the administration of SCH23390 followed by creatine administration increased the number of crossings and rearings in the open-field test. Reports revealed that SCH23390 at low doses caused a stimulation of forward locomotion in D-amphetamine-treated rats and an enhancement on apomorphine-induced locomotor activity in mice, suggesting that SCH23390 potentiates the locomotion under conditions of an increased general tone at brain dopamine or D<sub>2</sub> receptor stimulation (<xref ref-type="bibr" rid="bibr37-0269881112447989">Matsumoto et al., 1991</xref>; <xref ref-type="bibr" rid="bibr53-0269881112447989">Salmi et al., 1998</xref>). Moreover, dopamine D<sub>1</sub> receptor agonists produced an anti-immobility effect in the FST (<xref ref-type="bibr" rid="bibr22-0269881112447989">D’Aquila et al., 1994</xref>), corroborating with the present study, which shows that SKF38393 presented an antidepressant-like profile in the TST that was prevented by SCH23390 (<xref ref-type="fig" rid="fig4-0269881112447989">Figure 4(b)</xref>). Furthermore, the results in this study indicated that creatine administered at a sub-effective dose exerted a synergistic anti-immobility effect when associated with a sub-effective dose of SKF38393 in the TST. Somewhat in agreement with our result, <xref ref-type="bibr" rid="bibr50-0269881112447989">Renard et al. (2001)</xref> demonstrated that the dopamine D<sub>1</sub> receptor agonist SKF38393 enhanced the anti-immobility effect of antidepressants in the FST.</p>
<p>Our results also suggest that the effect of creatine in the TST is dependent on an interaction with dopamine D<sub>2</sub> receptors, since the pre-treatment of mice with haloperidol or sulpiride prevented the antidepressant-like effect evoked by creatine in the TST. Our recent studies have reported that sulpiride prevented the antidepressant-like effect of antidepressant drugs in the TST (<xref ref-type="bibr" rid="bibr35-0269881112447989">Machado et al., 2007</xref>, <xref ref-type="bibr" rid="bibr34-0269881112447989">2009</xref>; <xref ref-type="bibr" rid="bibr9-0269881112447989">Binfaré et al., 2010</xref>; <xref ref-type="bibr" rid="bibr13-0269881112447989">Capra et al., 2010</xref>; <xref ref-type="bibr" rid="bibr23-0269881112447989">Freitas et al., 2010</xref>). Moreover, sulpiride prevented the antidepressant-like effect of two dopamine reuptake inhibitors, bupropion and nomifensine, in the FST (<xref ref-type="bibr" rid="bibr65-0269881112447989">Yamada et al., 2004</xref>; <xref ref-type="bibr" rid="bibr39-0269881112447989">Melo et al., 2011</xref>). Furthermore, electroconvulsive therapy (ECT), used to treat depression resistant to the usual antidepressant drugs, causes a reduction in the immobility time in the TST, which was antagonized by sulpiride, implicating the dopamine D<sub>2</sub> receptor in the antidepressant-like action of ECT (<xref ref-type="bibr" rid="bibr60-0269881112447989">Teste et al., 1990</xref>). The dopamine D<sub>2</sub> receptor stimulant LY171555 reduced the immobility time in the FST, indicating that activation of dopamine D<sub>2</sub> receptors could reduce immobility time in this test (<xref ref-type="bibr" rid="bibr11-0269881112447989">Borsini et al., 1989</xref>). Accordingly, in the present study apomorphine produced an antidepressant-like profile in the TST, an effect that was prevented by sulpiride (<xref ref-type="fig" rid="fig5-0269881112447989">Figure 5(b)</xref>). In line with our results, a dopamine D<sub>2</sub> receptor agonist, bromocriptine, was effective against tricyclic and heterocyclic antidepressant-resistant depression (<xref ref-type="bibr" rid="bibr28-0269881112447989">Inoue et al., 1996</xref>). Our results indicated that creatine at a sub-effective dose exerted synergistic anti-immobility effect when associated with a sub-effective dose of apomorphine in the TST. Altogether, the results indicate that an activation of dopamine D<sub>1</sub> and D<sub>2</sub> receptors is likely implicated in the antidepressant-like effect of creatine in the TST.</p>
<p>Bupropion and amineptine, dopamine reuptake inhibitors with subtle activity on noradrenergic reuptake (<xref ref-type="bibr" rid="bibr17-0269881112447989">Cooper et al., 1980</xref>; <xref ref-type="bibr" rid="bibr25-0269881112447989">Garattini, 1997</xref>; <xref ref-type="bibr" rid="bibr51-0269881112447989">Richelson, 2003</xref>), produce antidepressant-like properties in the TST (<xref ref-type="bibr" rid="bibr61-0269881112447989">Teste et al., 1993</xref>; <xref ref-type="bibr" rid="bibr19-0269881112447989">Cunha et al., 2008</xref>). Furthermore, our recent studies have reported that bupropion, administered at a sub-effective dose, elicited a synergistic antidepressant-like effect when associated with sub-effective doses of potential antidepressant agents in the TST (<xref ref-type="bibr" rid="bibr19-0269881112447989">Cunha et al., 2008</xref>; <xref ref-type="bibr" rid="bibr9-0269881112447989">Binfaré et al., 2010</xref>; <xref ref-type="bibr" rid="bibr23-0269881112447989">Freitas et al., 2010</xref>). In our study, bupropion produced a synergistic antidepressant-like effect when combined with creatine in the TST. This is, to our knowledge, the first evidence that creatine is able to cause a synergistic antidepressant-effect with this antidepressant. This suggests that creatine might improve the effectiveness of bupropion in the therapy of human depression. In line with this hypothesis, a clinical study has shown that creatine supplementation for two years led to a smaller dose increase of dopaminergic therapy in patients with Parkinson’s disease (<xref ref-type="bibr" rid="bibr7-0269881112447989">Bender et al., 2006</xref>). Thus, it is tempting to speculate that an activation of the dopaminergic system elicited by creatine may be a mechanism underlying its antidepressant-like effect that may be beneficial for the treatment of depression associated with anhedonia. This hypothesis deserves future studies to investigate the involvement of the dopaminergic system in the antidepressant-like effect of creatine in animal models that resemble human depression, like chronic mild stress.</p>
<p>In conclusion, the results presented herein indicate that the antidepressant-like action of creatine seems to be mediated by a stimulation of the dopamine D<sub>1</sub> and D<sub>2</sub> receptors and possibly a modulation on dopamine reuptake. This is in agreement with previous pre-clinical and clinical findings which show that compounds that affect the dopaminergic transmission might produce an antidepressant action (<xref ref-type="bibr" rid="bibr11-0269881112447989">Borsini et al., 1989</xref>; <xref ref-type="bibr" rid="bibr22-0269881112447989">D’Aquila et al., 1994</xref>) and improve outcomes of patients with treatment-resistant and non-remitting depression (<xref ref-type="bibr" rid="bibr28-0269881112447989">Inoue et al., 1996</xref>). However, the results obtained with the TST should be considered with caution and further animal studies and neurochemical measurements that could confirm the interaction of creatine with the dopaminergic system are welcome.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This study was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (grant # 307687/2009-0), Coordenação de Aperfeiçoamento de Pessoal de Ensino Superior (CAPES), Fundação de Apoio a Pesquisa Científica e Tecnológica do Estado de Santa Catarina (FAPESC) (grant # 1347/2010-1), Rede Instituto Brasileiro de Neurociência (IBN-Net/CNPq) and (NENASC) project /PRONEX program CNPq/FAPESC.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>The authors declare no conflict of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Allen</surname><given-names>PJ</given-names></name>
<name><surname>D’Anci</surname><given-names>KE</given-names></name>
<name><surname>Kanarek</surname><given-names>RB</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Chronic creatine supplementation alters depression-like behavior in rodents in a sex-dependent manner</article-title>. <source>Neuropsychopharmacology</source> <volume>35</volume>: <fpage>534</fpage>–<lpage>546</lpage>.</citation>
</ref>
<ref id="bibr2-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amital</surname><given-names>D</given-names></name>
<name><surname>Vishne</surname><given-names>T</given-names></name>
<name><surname>Roitman</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Open study of creatine monohydrate in treatment-resistant posttraumatic stress disorder</article-title>. <source>J Clin Psychiatry</source> <volume>67</volume>: <fpage>836</fpage>–<lpage>837</lpage>.</citation>
</ref>
<ref id="bibr3-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andres</surname><given-names>RH</given-names></name>
<name><surname>Ducray</surname><given-names>AD</given-names></name>
<name><surname>Schlattner</surname><given-names>U</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Functions and effects of creatine in the central nervous system</article-title>. <source>Brain Res Bull</source> <volume>76</volume>: <fpage>329</fpage>–<lpage>343</lpage>.</citation>
</ref>
<ref id="bibr4-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andres</surname><given-names>RH</given-names></name>
<name><surname>Huber</surname><given-names>AW</given-names></name>
<name><surname>Schlattner</surname><given-names>U</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue</article-title>. <source>Neuroscience</source> <volume>133</volume>: <fpage>701</fpage>–<lpage>713</lpage>.</citation>
</ref>
<ref id="bibr5-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Assis</surname><given-names>LC</given-names></name>
<name><surname>Rezin</surname><given-names>GT</given-names></name>
<name><surname>Comim</surname><given-names>CM</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Effect of acute administration of ketamine and imipramine on creatine kinase activity in the brain of rats</article-title>. <source>Rev Bras Psiquiatr</source> <volume>31</volume>: <fpage>247</fpage>–<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr6-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Becker</surname><given-names>C</given-names></name>
<name><surname>Brobert</surname><given-names>GP</given-names></name>
<name><surname>Johansson</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Risk of incident depression in patients with Parkinson disease in the UK</article-title>. <source>Eur J Neurol</source> <volume>18</volume>: <fpage>448</fpage>–<lpage>453</lpage>.</citation>
</ref>
<ref id="bibr7-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bender</surname><given-names>A</given-names></name>
<name><surname>Koch</surname><given-names>W</given-names></name>
<name><surname>Elstner</surname><given-names>M</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial</article-title>. <source>Neurology</source> <volume>67</volume>: <fpage>1262</fpage>–<lpage>1264</lpage>.</citation>
</ref>
<ref id="bibr8-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berton</surname><given-names>O</given-names></name>
<name><surname>Nestler</surname><given-names>EJ</given-names></name>
</person-group> (<year>2006</year>) <article-title>New approaches to antidepressant drug discovery: Beyond monoamines</article-title>. <source>Nature Rev Neurosci</source> <volume>7</volume>: <fpage>137</fpage>–<lpage>151</lpage>.</citation>
</ref>
<ref id="bibr9-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Binfaré</surname><given-names>RW</given-names></name>
<name><surname>Mantovani</surname><given-names>M</given-names></name>
<name><surname>Budni</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Involvement of dopamine receptors in the antidepressant-like effect of melatonin in the tail suspension test</article-title>. <source>Eur J Pharmacol</source> <volume>638</volume>: <fpage>78</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr10-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Borsini</surname><given-names>F</given-names></name>
<name><surname>Meli</surname><given-names>A</given-names></name>
</person-group> (<year>1988</year>) <article-title>Is the forced swimming test a suitable model for revealing antidepressant activity?</article-title> <source>Psychopharmacology</source> <volume>94</volume>: <fpage>147</fpage>–<lpage>160</lpage>.</citation>
</ref>
<ref id="bibr11-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Borsini</surname><given-names>F</given-names></name>
<name><surname>Lecci</surname><given-names>A</given-names></name>
<name><surname>Sessarego</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>1989</year>) <article-title>Discovery of antidepressant activity by forced swimming test may depend on pre-exposure of rats to a stressful situation</article-title>. <source>Psychopharmacology</source> <volume>97</volume>: <fpage>183</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr12-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burroughs</surname><given-names>S</given-names></name>
<name><surname>French</surname><given-names>D</given-names></name>
</person-group> (<year>2007</year>) <article-title>Depression and anxiety: Role of mitochondria</article-title>. <source>Curr Anaesth Crit Care</source> <volume>18</volume>: <fpage>34</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr13-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Capra</surname><given-names>JC</given-names></name>
<name><surname>Cunha</surname><given-names>MP</given-names></name>
<name><surname>Machado</surname><given-names>DG</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Antidepressant-like effect of scopoletin, a coumarin isolated from <italic>Polygala sabulosa</italic> (Polygalaceae) in mice: Evidence for the involvement of monoaminergic systems</article-title>. <source>Eur J Pharmacol</source> <volume>643</volume>: <fpage>232</fpage>–<lpage>238</lpage>.</citation>
</ref>
<ref id="bibr14-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cardoso</surname><given-names>CC</given-names></name>
<name><surname>Lobato</surname><given-names>KR</given-names></name>
<name><surname>Binfaré</surname><given-names>RW</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Evidence for the involvement of the monoaminergic system in the antidepressant-like effect of magnesium</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <volume>33</volume>: <fpage>235</fpage>–<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr15-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>AV</given-names></name>
<name><surname>Arnt</surname><given-names>J</given-names></name>
<name><surname>Hyttel</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>1984</year>) <article-title>Pharmacological effects of a specific dopamine D<sub>1</sub> antagonist SCH23390 in comparison with neuroleptics</article-title>. <source>Life Sci</source> <volume>34</volume>: <fpage>1529</fpage>–<lpage>1540</lpage>.</citation>
</ref>
<ref id="bibr16-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clausius</surname><given-names>N</given-names></name>
<name><surname>Born</surname><given-names>C</given-names></name>
<name><surname>Grunze</surname><given-names>H</given-names></name>
</person-group> (<year>2009</year>) <article-title>The relevance of dopamine agonists in the treatment of depression</article-title>. <source>Neuropsychiatry</source> <volume>23</volume>: <fpage>15</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr17-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cooper</surname><given-names>BR</given-names></name>
<name><surname>Hester</surname><given-names>TJ</given-names></name>
<name><surname>Maxwell</surname><given-names>RA</given-names></name>
</person-group> (<year>1980</year>) <article-title>Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): Evidence for selective blockade of dopamine uptake in vivo</article-title>. <source>J Pharmacol Exp Ther</source> <volume>215</volume>: <fpage>127</fpage>–<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr18-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cryan</surname><given-names>JF</given-names></name>
<name><surname>Mombereau</surname><given-names>C</given-names></name>
<name><surname>Vassout</surname><given-names>A</given-names></name>
</person-group> (<year>2005</year>) <article-title>The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice</article-title>. <source>Neurosci Biobehav Rev</source> <volume>29</volume>: <fpage>571</fpage>–<lpage>625</lpage>.</citation>
</ref>
<ref id="bibr19-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cunha</surname><given-names>MP</given-names></name>
<name><surname>Machado</surname><given-names>DG</given-names></name>
<name><surname>Bettio</surname><given-names>LEB</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Interaction of zinc with antidepressants in the tail suspension test</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <volume>32</volume>: <fpage>1913</fpage>–<lpage>1920</lpage>.</citation>
</ref>
<ref id="bibr20-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dager</surname><given-names>SR</given-names></name>
<name><surname>Friedman</surname><given-names>SD</given-names></name>
<name><surname>Parow</surname><given-names>A</given-names></name>
</person-group> (<year>2004</year>) <article-title>Brain metabolic alterations in medication-free patients with bipolar disorder</article-title>. <source>Arch Gen Psychiatry</source> <volume>61</volume>: <fpage>450</fpage>–<lpage>458</lpage>.</citation>
</ref>
<ref id="bibr21-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>D’Aquila</surname><given-names>PS</given-names></name>
<name><surname>Collu</surname><given-names>M</given-names></name>
<name><surname>Gessa</surname><given-names>GL</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>The role of dopamine in the mechanism of action of antidepressants drugs</article-title>. <source>Eur J Pharmacol</source> <volume>405</volume>: <fpage>365</fpage>–<lpage>373</lpage>.</citation>
</ref>
<ref id="bibr22-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>D’Aquila</surname><given-names>PS</given-names></name>
<name><surname>Collu</surname><given-names>M</given-names></name>
<name><surname>Pani</surname><given-names>L</given-names></name><etal/>
</person-group>. (<year>1994</year>) <article-title>Antidepressant-like effect of selective dopamine D<sub>1</sub> receptor agonists in the behavioural despair animal model of depression</article-title>. <source>Eur J Pharmacol</source> <volume>262</volume>: <fpage>107</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr23-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freitas</surname><given-names>AE</given-names></name>
<name><surname>Budni</surname><given-names>J</given-names></name>
<name><surname>Lobato</surname><given-names>KR</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Antidepressant-like action of the ethanolic extract from <italic>Tabebuia avellanedae</italic> in mice: Evidence for the involvement of the monoaminergic system</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <volume>34</volume>: <fpage>335</fpage>–<lpage>343</lpage>.</citation>
</ref>
<ref id="bibr24-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gambarana</surname><given-names>C</given-names></name>
<name><surname>Ghiglieri</surname><given-names>O</given-names></name>
<name><surname>Tagliamonte</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>1995</year>) <article-title>Crucial role of D<sub>1</sub> dopamine receptors in mediating the antidepressant effect of imipramine</article-title>. <source>Pharmacol Biochem Behav</source> <volume>50</volume>: <fpage>147</fpage>–<lpage>151</lpage>.</citation>
</ref>
<ref id="bibr25-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garattini</surname><given-names>S</given-names></name>
</person-group> (<year>1997</year>) <article-title>Pharmacology of amineptine, an antidepressant agent acting on the dopaminergic system: A review</article-title>. <source>Int Clin Psychopharmacol</source> <volume>12</volume>: <fpage>S15</fpage>–<lpage>S19</lpage>.</citation>
</ref>
<ref id="bibr26-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hyttel</surname><given-names>J</given-names></name>
</person-group> (<year>1984</year>) <article-title>Functional evidence for selective dopamine D-1 receptor blockade by SCH23390</article-title>. <source>Neuropharmacology</source> <volume>23</volume>: <fpage>1395</fpage>–<lpage>1401</lpage>.</citation>
</ref>
<ref id="bibr27-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holtzheimer</surname><given-names>PE</given-names></name>
<name><surname>Nemeroff</surname><given-names>CB</given-names></name>
</person-group> (<year>2006</year>) <article-title>Advances in the treatment of depression</article-title>. <source>J NeuroRx</source> <volume>3</volume>: <fpage>42</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr28-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Inoue</surname><given-names>T</given-names></name>
<name><surname>Tsuchiya</surname><given-names>K</given-names></name>
<name><surname>Miura</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>1996</year>) <article-title>Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression</article-title>. <source>Biol Psychiatry</source> <volume>40</volume>: <fpage>151</fpage>–<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr29-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kato</surname><given-names>T</given-names></name>
<name><surname>Takahashi</surname><given-names>S</given-names></name>
<name><surname>Shioiri</surname><given-names>T</given-names></name><etal/>
</person-group>. (<year>1992</year>) <article-title>Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy</article-title>. <source>J Affect Disord</source> <volume>26</volume>: <fpage>223</fpage>–<lpage>230</lpage>.</citation>
</ref>
<ref id="bibr30-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ketter</surname><given-names>TA</given-names></name>
<name><surname>Kimbrell</surname><given-names>TA</given-names></name>
<name><surname>George</surname><given-names>MS</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder</article-title>. <source>Biol Psychiatry</source> <volume>49</volume>: <fpage>97</fpage>–<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr31-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>SY</given-names></name>
<name><surname>Lee</surname><given-names>YJ</given-names></name>
<name><surname>Kim</surname><given-names>H</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Desipramine attenuates forced swim test-induced behavioral and neurochemical alterations in mice: An in vivo(1)H-MRS study at 9.4T</article-title>. <source>Brain Res</source> <volume>1348</volume>: <fpage>105</fpage>–<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr32-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kulkarni</surname><given-names>SK</given-names></name>
<name><surname>Bhutani</surname><given-names>MK</given-names></name>
<name><surname>Bishnoi</surname><given-names>M</given-names></name>
</person-group> (<year>2008</year>) <article-title>Antidepressant activity of curcumin: Involvement of serotonin and dopamine system</article-title>. <source>Psychopharmacology</source> <volume>201</volume>: <fpage>435</fpage>–<lpage>442</lpage>.</citation>
</ref>
<ref id="bibr33-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leuchter</surname><given-names>AF</given-names></name>
<name><surname>Cook</surname><given-names>IA</given-names></name>
<name><surname>Gilmer</surname><given-names>WS</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder</article-title>. <source>Psychiatry Res</source> <volume>169</volume>: <fpage>132</fpage>–<lpage>138</lpage>.</citation>
</ref>
<ref id="bibr34-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Machado</surname><given-names>DG</given-names></name>
<name><surname>Bettio</surname><given-names>LEB</given-names></name>
<name><surname>Cunha</surname><given-names>MP</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Antidepressant-like effect of the extract of <italic>Rosmarinus ofﬁcinalis</italic> in mice: Involvement of the monoaminergic system</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <volume>33</volume>: <fpage>642</fpage>–<lpage>650</lpage>.</citation>
</ref>
<ref id="bibr35-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Machado</surname><given-names>DG</given-names></name>
<name><surname>Kaster</surname><given-names>MP</given-names></name>
<name><surname>Binfaré</surname><given-names>RW</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Antidepressant-like effect of the extract from leaves of <italic>Schinus molle</italic> L. in mice: Evidence for the involvement of the monoaminergic system</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <volume>31</volume>: <fpage>421</fpage>–<lpage>428</lpage>.</citation>
</ref>
<ref id="bibr36-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McMorris</surname><given-names>T</given-names></name>
<name><surname>Harris</surname><given-names>RC</given-names></name>
<name><surname>Swain</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Effect of creatine supplementation and sleep deprivation, with mild exercise, on cognitive and psychomotor performance, mood state, and plasma concentrations of catecholamines and cortisol</article-title>. <source>Psychopharmacology</source> <volume>186</volume>: <fpage>93</fpage>–<lpage>103</lpage>.</citation>
</ref>
<ref id="bibr37-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matsumoto</surname><given-names>K</given-names></name>
<name><surname>Cai</surname><given-names>B</given-names></name>
<name><surname>Ohta</surname><given-names>H</given-names></name><etal/>
</person-group>. (<year>1991</year>) <article-title>Apparent enhancement by SCH23390 of apomorphine-induced locomotor activity in mice</article-title>. <source>Pharmacol Biochem Behav</source> <volume>39</volume>: <fpage>699</fpage>–<lpage>703</lpage>.</citation>
</ref>
<ref id="bibr38-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matthews</surname><given-names>RT</given-names></name>
<name><surname>Ferrante</surname><given-names>RJ</given-names></name>
<name><surname>Klivenyi</surname><given-names>P</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Creatine and cyclocreatine attenuate MPTP neurotoxicity</article-title>. <source>Exp Neurol</source> <volume>157</volume>: <fpage>142</fpage>–<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr39-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Melo</surname><given-names>FH</given-names></name>
<name><surname>Moura</surname><given-names>BA</given-names></name>
<name><surname>de Sousa</surname><given-names>DP</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Antidepressant-like effect of carvacrol (5-Isopropyl-2-methylphenol) in mice: Involvement of dopaminergic system</article-title>. <source>Fundam Clin Pharmacol</source> <volume>25</volume>: <fpage>362</fpage>–<lpage>367</lpage>.</citation>
</ref>
<ref id="bibr40-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Millan</surname><given-names>MJ</given-names></name>
<name><surname>Maiofiss</surname><given-names>L</given-names></name>
<name><surname>Cussac</surname><given-names>D</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes</article-title>. <source>J Pharmacol Exp Ther</source> <volume>303</volume>: <fpage>791</fpage>–<lpage>804</lpage>.</citation>
</ref>
<ref id="bibr41-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Missale</surname><given-names>C</given-names></name>
<name><surname>Nash</surname><given-names>SR</given-names></name>
<name><surname>Robinson</surname><given-names>SW</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Dopamine receptors: From structure to function</article-title>. <source>Physiol Rev</source> <volume>78</volume>: <fpage>189</fpage>–<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr42-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mitani</surname><given-names>H</given-names></name>
<name><surname>Shirayama</surname><given-names>Y</given-names></name>
<name><surname>Yamada</surname><given-names>T</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Plasma levels of homovanillic acid, 5-hydroxyindoleacetic acid and cortisol, and serotonin turnover in depressed patients</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <volume>30</volume>: <fpage>531</fpage>–<lpage>534</lpage>.</citation>
</ref>
<ref id="bibr43-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moore</surname><given-names>CM</given-names></name>
<name><surname>Christensen</surname><given-names>JD</given-names></name>
<name><surname>Lafer</surname><given-names>B</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: A phosphorous-31 magnetic resonance spectroscopy study</article-title>. <source>Am J Psychiatry</source> <volume>154</volume>: <fpage>116</fpage>–<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr44-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moretti</surname><given-names>A</given-names></name>
<name><surname>Gorini</surname><given-names>A</given-names></name>
<name><surname>Villa</surname><given-names>RF</given-names></name>
</person-group> (<year>2003</year>) <article-title>Affective disorders, antidepressant drugs and brain metabolism</article-title>. <source>Mol Psychiatry</source> <volume>8</volume>: <fpage>773</fpage>–<lpage>785</lpage>.</citation>
</ref>
<ref id="bibr45-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nemeroff</surname><given-names>CB</given-names></name>
<name><surname>Owens</surname><given-names>MJ</given-names></name>
</person-group> (<year>2002</year>) <article-title>Treatment of mood disorders</article-title>. <source>Nature Neurosci</source> <volume>5</volume> (<supplement>Suppl.</supplement>): <fpage>1068</fpage>–<lpage>1070</lpage>.</citation>
</ref>
<ref id="bibr46-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nestler</surname><given-names>EJ</given-names></name>
<name><surname>Carlezon</surname><given-names>WA</given-names><suffix>Jr</suffix></name>
</person-group> (<year>2006</year>) <article-title>The mesolimbic dopamine reward circuit in depression</article-title>. <source>Biol Psychiatry</source> <volume>59</volume>: <fpage>1151</fpage>–<lpage>1159</lpage>.</citation>
</ref>
<ref id="bibr47-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nikulina</surname><given-names>EM</given-names></name>
<name><surname>Skrinskaya</surname><given-names>JA</given-names></name>
<name><surname>Popova</surname><given-names>NK</given-names></name>
</person-group> (<year>1991</year>) <article-title>Role of genotype and dopamine receptors in behaviour of inbred mice in a forced swimming test</article-title>. <source>Psychopharmacology</source> <volume>105</volume>: <fpage>525</fpage>–<lpage>529</lpage>.</citation>
</ref>
<ref id="bibr48-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ongür</surname><given-names>D</given-names></name>
<name><surname>Prescot</surname><given-names>AP</given-names></name>
<name><surname>Jensen</surname><given-names>JE</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Creatine abnormalities in schizophrenia and bipolar disorder</article-title>. <source>Psychiatry Res</source> <volume>172</volume>: <fpage>44</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr49-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Papakostas</surname><given-names>GI</given-names></name>
</person-group>. (<year>2009</year>) <article-title>Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder</article-title>. <source>J Clin Psychiatry</source> <volume>70</volume>: <fpage>18</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr50-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Renard</surname><given-names>CE</given-names></name>
<name><surname>Fiocco</surname><given-names>AJ</given-names></name>
<name><surname>Clenet</surname><given-names>F</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test?</article-title> <source>Psychopharmacology</source> <volume>159</volume>: <fpage>42</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr51-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Richelson</surname><given-names>E</given-names></name>
</person-group> (<year>2003</year>) <article-title>Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance</article-title>. <source>J Clin Psychiatry</source> <volume>64</volume>: <fpage>5</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr52-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roitman</surname><given-names>S</given-names></name>
<name><surname>Green</surname><given-names>T</given-names></name>
<name><surname>Osher</surname><given-names>Y</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Creatine monohydrate in resistant depression: A preliminary study</article-title>. <source>Bipolar Disord</source> <volume>9</volume>: <fpage>754</fpage>–<lpage>758</lpage>.</citation>
</ref>
<ref id="bibr53-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salmi</surname><given-names>P</given-names></name>
<name><surname>Malmgren</surname><given-names>K</given-names></name>
<name><surname>Svensson</surname><given-names>TH</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Stimulation of forward locomotion by SCH-23390 and raclopride in d-amphetamine-treated rats</article-title>. <source>Naunyn Schmiedebergs Arch Pharmacol</source> <volume>357</volume>: <fpage>593</fpage>–<lpage>599</lpage>.</citation>
</ref>
<ref id="bibr54-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sher</surname><given-names>L</given-names></name>
<name><surname>Mann</surname><given-names>JJ</given-names></name>
<name><surname>Traskman-Bendz</surname><given-names>L</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Lower cerebrospinal fluid homovanillic acid levels in depressed suicide attempters</article-title>. <source>J Affect Disord</source> <volume>90</volume>: <fpage>83</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr55-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shimazu</surname><given-names>S</given-names></name>
<name><surname>Minami</surname><given-names>A</given-names></name>
<name><surname>Kusumoto</surname><given-names>H</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Antidepressant-like effects of selegiline in the forced swim test</article-title>. <source>Eur Neuropsychopharmacol</source> <volume>15</volume>: <fpage>563</fpage>–<lpage>571</lpage>.</citation>
</ref>
<ref id="bibr56-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Siris</surname><given-names>SG</given-names></name>
</person-group> (<year>2000</year>) <article-title>Depression in schizophrenia: Perspective in the era of ‘Atypical’ antipsychotic agents</article-title>. <source>Am J Psychiatry</source> <volume>157</volume>: <fpage>1379</fpage>–<lpage>1389</lpage>.</citation>
</ref>
<ref id="bibr57-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Siuciak</surname><given-names>JA</given-names></name>
<name><surname>Fujiwara</surname><given-names>RA</given-names></name>
</person-group> (<year>2004</year>) <article-title>The activity of pramipexole in the mouse forced swim test is mediated by D<sub>2</sub> rather than D<sub>3</sub> receptors</article-title>. <source>Psychopharmacology</source> <volume>175</volume>: <fpage>163</fpage>–<lpage>169</lpage>.</citation>
</ref>
<ref id="bibr58-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steru</surname><given-names>L</given-names></name>
<name><surname>Chermat</surname><given-names>R</given-names></name>
<name><surname>Thierry</surname><given-names>B</given-names></name><etal/>
</person-group>. (<year>1985</year>) <article-title>The tail suspension test: A new method for screening antidepressants in mice</article-title>. <source>Psychopharmacology</source> <volume>85</volume>: <fpage>367</fpage>–<lpage>370</lpage>.</citation>
</ref>
<ref id="bibr59-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stoof</surname><given-names>JC</given-names></name>
<name><surname>Kebabian</surname><given-names>JW</given-names></name>
</person-group> (<year>1984</year>) <article-title>Two dopamine receptors: Biochemistry, physiology and pharmacology</article-title>. <source>Life Sci</source> <volume>35</volume>: <fpage>2281</fpage>–<lpage>2296</lpage>.</citation>
</ref>
<ref id="bibr60-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Teste</surname><given-names>JF</given-names></name>
<name><surname>Martin</surname><given-names>I</given-names></name>
<name><surname>Rinjard</surname><given-names>P</given-names></name>
</person-group> (<year>1990</year>) <article-title>Electrotherapy in mice: Dopaminergic and noradrenergic effects in the tail suspension test</article-title>. <source>Fundam Clin Pharmacol</source> <volume>4</volume>: <fpage>39</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr61-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Teste</surname><given-names>JF</given-names></name>
<name><surname>Pelsy-Johann</surname><given-names>I</given-names></name>
<name><surname>Decelle</surname><given-names>T</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Anti-immobility activity of different antidepressant drugs using the tail suspension test in normal or reserpinized mice</article-title>. <source>Fundam Clin Pharmacol</source> <volume>7</volume>: <fpage>219</fpage>–<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr62-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vamvakidès</surname><given-names>A</given-names></name>
</person-group> (<year>1999</year>) <article-title>Effect of presynaptic dopaminergic agonism on the immobility of mice in the forced swimming test</article-title>. <source>Ann Pharm Fr</source> <volume>57</volume>: <fpage>374</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr63-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wong</surname><given-names>ML</given-names></name>
<name><surname>Licinio</surname><given-names>J</given-names></name>
</person-group> (<year>2001</year>) <article-title>Research and treatment approaches to depression</article-title>. <source>Nature Rev Neurosci</source> <volume>2</volume>: <fpage>343</fpage>–<lpage>351</lpage>.</citation>
</ref>
<ref id="bibr64-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Volz</surname><given-names>HP</given-names></name>
<name><surname>Rzanny</surname><given-names>R</given-names></name>
<name><surname>Riehemann</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>1998</year>) <sup>31</sup>P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. <source>Eur Arch Psychiatry Clin Neurosci</source> <volume>248</volume>: <fpage>289</fpage>–<lpage>295</lpage>.</citation>
</ref>
<ref id="bibr65-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yamada</surname><given-names>J</given-names></name>
<name><surname>Sugimoto</surname><given-names>Y</given-names></name>
<name><surname>Yamada</surname><given-names>S</given-names></name>
</person-group> (<year>2004</year>) <article-title>Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test</article-title>. <source>Eur J Pharmacol</source> <volume>504</volume>: <fpage>207</fpage>–<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr66-0269881112447989">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zarrindast</surname><given-names>MR</given-names></name>
<name><surname>Moghaddampour</surname><given-names>E</given-names></name>
</person-group> (<year>1989</year>) <article-title>Opposing influences of D-1 and D-2 dopamine receptors activation on morphine-induced antinociception</article-title>. <source>Arch Int Pharmacodyn Ther</source> <volume>300</volume>: <fpage>37</fpage>–<lpage>50</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>